Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON CLAD: Ferric carboxymaltose for cancer- and chemotherapy-related anemia
2016-002021-11Phase 3Completed
- Sponsor
- Luitpold Pharmaceuticals
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-associated anemia (CRA) and anaemia comparing Ferric carboxymaltose (Injectafer) with Placebo (2 arms). Primary endpoint: Hemoglobin decrease ≥0.5 g/dL from baseline. Started May 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
cancer-associated anemia (CRA)anaemia
Beyond the preview
Go deeper on 2016-002021-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002021-11.